GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Shiller PE Ratio

BriaCell Therapeutics (TSX:BCT) Shiller PE Ratio : (As of May. 29, 2024)


View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BriaCell Therapeutics Shiller PE Ratio Historical Data

The historical data trend for BriaCell Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Shiller PE Ratio Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BriaCell Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, BriaCell Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Shiller PE Ratio falls into.



BriaCell Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BriaCell Therapeutics's E10 for the quarter that ended in Jan. 2024 is calculated as:

For example, BriaCell Therapeutics's adjusted earnings per share data for the three months ended in Jan. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.953/125.0724*125.0724
=-0.953

Current CPI (Jan. 2024) = 125.0724.

BriaCell Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201404 -9.783 98.920 -12.369
201407 -134.425 99.315 -169.288
201410 -0.346 99.473 -0.435
201501 -11.427 98.209 -14.553
201504 -3.078 99.710 -3.861
201507 -1.994 100.579 -2.480
201510 -3.000 100.500 -3.733
201601 -3.050 100.184 -3.808
201604 -3.063 101.370 -3.779
201607 -2.634 101.844 -3.235
201610 -2.963 102.002 -3.633
201701 -3.018 102.318 -3.689
201704 -5.909 103.029 -7.173
201707 -11.955 103.029 -14.513
201710 -2.948 103.424 -3.565
201801 -3.023 104.056 -3.634
201804 -2.974 105.320 -3.532
201807 9.163 106.110 10.800
201810 -1.914 105.952 -2.259
201901 -2.947 105.557 -3.492
201904 -2.580 107.453 -3.003
201907 -3.461 108.243 -3.999
201910 -2.414 107.927 -2.797
202001 -2.585 108.085 -2.991
202004 -0.982 107.216 -1.146
202007 -1.800 108.401 -2.077
202010 -0.714 108.638 -0.822
202101 -0.382 109.192 -0.438
202104 0.787 110.851 0.888
202107 -1.322 112.431 -1.471
202110 -2.251 113.695 -2.476
202201 0.896 114.801 0.976
202204 -0.821 118.357 -0.868
202207 -0.039 120.964 -0.040
202210 -0.096 121.517 -0.099
202301 -1.033 121.596 -1.063
202304 -0.431 123.571 -0.436
202307 -0.198 124.914 -0.198
202310 -0.686 125.310 -0.685
202401 -0.953 125.072 -0.953

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BriaCell Therapeutics  (TSX:BCT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BriaCell Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (TSX:BCT) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Executives
Jamieson Bondarenko Director

BriaCell Therapeutics (TSX:BCT) Headlines

No Headlines